Russell Portenoy

Russell Portenoy is presented as a prominent pain physician and the elder statesman of pain management, whose confidence in expanding opioid treatment collided with Art Van Zee’s challenge to the evidence on addiction risk. Their brief exchange over OxyContin concentrates a larger dispute into a practical question: how much risk could be accepted in the effort to treat chronic pain? The book later sets Portenoy’s position against his acknowledgment that pain doctors had overstated opioids’ benefits and discounted their dangers.

Identity and Position in Pain Medicine

Portenoy enters the account not as a marginal advocate but as an influential figure in pain medicine. The narrative’s description of him as the field’s elder statesman gives his response to Van Zee weight: this is a disagreement between a country doctor raising questions about risk and a prominent physician whose views helped represent the prevailing commitment to opioid treatment. The evidence does not supply a biography or a detailed account of Portenoy’s professional career; his significance here lies in the authority attached to his position in this debate.

That position was not simply that pain mattered. In their conversation, Portenoy argued that a greater supply of opioids would better meet the needs of chronic-pain patients. His stance sets the terms of the conflict: expanded access appeared to answer the problem of undertreated pain, while Van Zee pressed the question of what harms might accompany that expansion. The book presents the disagreement as a contest over both treatment and the standards used to judge its consequences.

The Exchange with Art Van Zee

The confrontation followed a public hearing in 2002. The next morning, Van Zee spoke with Portenoy for ten minutes and asked what level of addiction risk he considered acceptable for OxyContin. The question challenged the repeated use of a less-than-one-percent estimate drawn from a 1980 medical-journal letter. Van Zee pointed out that the figure was outdated and came from a hospital setting, not from the long-term use of pain medication at home. He asked whether it could meaningfully calculate risk for chronic-pain patients in ordinary life.

Van Zee made the challenge concrete by showing Portenoy a map of OxyContin distribution. It indicated that heightened crime and drug abuse overlapped with regions where prescribing was exceptionally high. In Lee County, Virginia, prescriptions ran at 300 to 600 percent above the national average. The map connected an argument about medical practice to conditions visible beyond the clinic: the question was not only whether a medicine could relieve pain, but what its wide circulation might mean in communities where it was heavily prescribed.

Portenoy’s reply affirmed the value of putting more opioids into circulation to meet chronic-pain needs. Van Zee then tested the position against a higher possible addiction risk, asking what collateral harm would be acceptable if the outcome were fifty thousand people addicted to opioids. The exchange ended without agreement: Portenoy, exasperated by Van Zee’s persistence, walked away. The account records no resolution of the numerical question. Instead, the departure leaves the central difference exposed: the case for increased treatment was being weighed against a scale of possible harm that Van Zee insisted could not be dismissed.

Evidence, Risk, and the Limits of the Debate

The disagreement turns partly on what counted as evidence. Van Zee had spent months searching for studies on long-term abuse risks among patients using painkillers. At the end of the hearing, he raised that absence with the committee’s chairman, another prominent pain doctor, who explained that such studies did not exist. That exchange is distinct from Portenoy’s conversation with Van Zee, but it sharpens the evidentiary context surrounding Portenoy’s confidence in broader opioid availability: the risks were being debated while the long-term research Van Zee sought was missing.

The narrative does not portray Portenoy as unaware that chronic pain required treatment; rather, it shows how agreement on that need could coexist with profound disagreement about risk. Portenoy emphasized meeting patients’ needs through greater availability. Van Zee asked whether the existing estimate of addiction risk applied to home use and what the human consequences would be if the real figure were substantially higher. By joining the distribution map to the question of acceptable collateral damage, Van Zee challenged the assumption that increased access could be evaluated only by its therapeutic promise.

Reputation and Retrospective Assessment

At the time, the reception of the dispute was unequal. Van Zee’s judgment was questioned and mocked; one Virginia health-care administrator recalled that he was dismissed as a rabble-rouser and a kook. That response contrasts with the authority the narrative assigns to Portenoy, but it does not establish that Portenoy personally mocked or discredited Van Zee. The distinction matters: the book describes a wider imbalance in whose concerns were treated as credible, rather than attributing every act of dismissal to the physician who argued for greater opioid availability.

About a decade later, Portenoy conceded to Wall Street Journal reporters that he and other pain doctors had mistakenly overstated the benefits of opioids while discounting their risks. The retrospective acknowledgment changes the meaning of the earlier exchange without making it a simple prediction fulfilled. Van Zee had questioned the reliability of the addiction estimate and asked what level of harm was acceptable; Portenoy’s later concession recognized a broader failure in how benefits and risks had been represented. The book’s portrait therefore holds two moments together: the confidence of the early debate and the later admission that its balance had been wrong.

Narrative Significance

Portenoy’s role is to make the conflict over opioid treatment legible through a specific disagreement between influential medical judgment and an early warning. The exchange does not reduce the issue to indifference toward pain on one side and concern for patients on the other. It shows how a commitment to treating chronic pain could support expanded opioid supply even while the long-term risks remained inadequately studied, and how Van Zee tried to make those risks visible through both a prescribing map and a question about consequences.

His later concession gives the episode a retrospective frame, while the account preserves the original asymmetry: when the warning was raised, Van Zee’s standing suffered and Portenoy’s position carried the force of established authority. Portenoy is thus significant not as the sole cause or representative of every decision in the opioid crisis, but as a prominent participant whose earlier defense of wider availability and later recognition of overstated benefits mark a consequential shift in the debate over pain treatment and addiction risk.